Black men less likely than White men to undergo prostatectomy despite similar COVID-19 risk factors, biopsy Gleason grade groups.
The combination improved progression-free survival.
The nomograms predicted overall and progression-free survival.
In a trial of men who volunteered for PSA screening, detection of clinically insignificant tumors and benign findings were reduced when prostate biopsy was performed only in those with positive MRI results.
Investigators zero in on mortality risk factors in patients with cancer who contract COVID-19.
Compared with before the pandemic, men undergoing radical prostatectomy during the pandemic were more likely to have extraprostatic disease, according to investigators.
Early results support a fully-powered trial of 18F-PSMA PET/CT for prostate cancer detection, according to the investigators.
A final analysis of the TITAN trial shows that apalutamide vs placebo added to ADT significantly lowers the risk of death and castration-resistant disease in men with metastatic castration-sensitive prostate cancer.
Obesity in men with metastatic castration-resistant prostate cancer is associated with decreased risks for all-cause and cancer-specific mortality compared with overweight and normal-weight men.
Study findings lend support to using mpMRI for prostate cancer detection.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported.
In high treatment benefit category, Black men less likely to receive definitive treatment than non-Black men.
Adding apalutamide to androgen deprivation therapy improved survival and delayed progression.
In a randomized controlled study, adding metformin to androgen deprivation therapy for low-tumor-volume metastatic hormone-sensitive prostate cancer significantly delayed development of castration-resistant disease.
Low-risk patients did not appear to benefit from adjuvant radiation.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Neoadjuvant androgen deprivation therapy prior to prostate cancer surgery is feasible, investigators noted.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.